secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269534
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Q3 net loss widens to $29.8M on warrant remeasurement; cash $40.5M
--------------------------------------------------------------------------

- Net loss $29.8M ($0.13/sh) vs $3.0M ($0.02) in Q3 2024; includes $26.6M non-cash warrant remeasurement.
- Revenue $3.7M, down ~$0.1M YoY; cash $40.5M expected to fund ops into Q2 2027.
- Entered collaboration with William Demant Invest for ReSonance (ANP1); up to $12M development funding.
- Positive 36-month OpRegen (RG6501) data in dry AMD presented at CTS 2025.
- First chronic SCI participant dosed in OPC1 DOSED study; no safety events at 60 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000119312525269534/0001193125-25-269534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000119312525269534/lctx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer